论文部分内容阅读
目的探讨胰激肽原酶与金水宝中西药联合共同治疗早期糖尿病肾病的疗效。方法将66例早期糖尿病肾病患者在严格控制血压、血脂、血糖基础上,随机分成对照组和治疗组,分别用胰激肽原酶、金水宝及二者联合应用三组。结果各组治疗前后对尿微量白蛋白排泄率(UAER)、尿白蛋白/尿肌酐(ACR)均有显著减少(P<0.01),但联合组优于单用药组(P<0.05)。结论胰激肽原酶与金水宝联合治疗早期糖尿病肾病优于单药组,延缓了糖尿病肾病的发展。
Objective To investigate the curative effect of pancreatic kallikrein combined with Jinshuibao in the treatment of early diabetic nephropathy. Methods Sixty-six patients with early diabetic nephropathy were randomly divided into control group and treatment group on the basis of strict control of blood pressure, blood lipids and blood glucose. Three groups of patients were treated with pancreatic kallikrein, Jin-Shui-Bao and their combination. Results Before and after treatment, the urinary albumin excretion rate (UAER) and urinary albumin / urine creatinine (ACR) were significantly decreased (P <0.01), but the combination group was better than the single drug group (P <0.05). Conclusions Pancreatic kallikrein and Jin-Bao combined treatment of early diabetic nephropathy is better than single-drug group, which delayed the development of diabetic nephropathy.